BridgeMD
New treatment option for Breast Cancer Female
Official title Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
ClinicalTrials.gov ID: NCT04133077
What this study is testing
What is blood samples collection?
blood samples collection is an investigational medicine, being studied as a potential treatment for breast cancer female.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
- Signature of the participation consent to the study,
- Affiliation to a social security scheme
- Major woman with:
- metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having...
You likely can't join if
- Pregnant woman
- Patient deprived of liberty by court or administrative decision
- In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy
- Refusal to participate in the study
See the full eligibility criteria
- ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
- Signature of the participation consent to the study,
- Affiliation to a social security scheme
- Major woman with:
- metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen...
- metaplastic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, treated by primary surgery with a tumor size of at least 15 mm on the specimen.
- an inflammatory TN breast cancer (T4d), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue...
- non-metaplastic or inflammatory TN breast cancer, histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The...
- Luminal B breast cancer (LB), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will...
- histologically proven metastatic TN or metastatic breast cancer with an operable metastasis whose residual size, after chemotherapy, is at least 10 mm on the specimen. Residual metastasis will be at least 15 mm on...
- Patients in a metastatic situation can be included regardless of the therapeutic line.
- Pregnant woman
- Patient deprived of liberty by court or administrative decision
- In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy
- Refusal to participate in the study
The study team makes the final eligibility decision.
Where it's taking place
- Clermont-Ferrand, Puy-de-Dôme, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Clermont-Ferrand, Puy-de-Dôme, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.